|
Market Cap (2-Jul) $6,688,690 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0.0016 |
IXC released this announcement to the ASX on 24 January 2022, 9:36. The announcement is marked as price sensitive, and is 10 page(s) in length and 484.39kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.456% short sold according to ASIC data. It was ranked the 301st most shorted stock on the ASX. It remains ranked 521st as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 24 January 2022, 9:36 |
| Notice of Investor Call and Appendix 4C | 21 January 2022, 10:02 |
| Change of Registry Address | 20 December 2021, 14:48 |
| UK R&D Tax Rebate | 20 December 2021, 11:53 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 